Year: 2024

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression completed enrolment of the double-blind phase in Q3 2024 Phase 1 clinical trial to evaluate proprietary aerosol delivery device in healthy volunteers is ongoing in the UK Cash, cash equivalents, other financial assets and marketable securities of $193.8 millionDUBLIN, Nov. 14, 2024 (GLOBE NEWSWIRE) — GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2024, and provided updates on its business. Business Updates GH001 in Patients with TRD GH001, our proprietary inhaled mebufotenin (5-MeO-DMT) product candidate, is currently being investigated in a multi-center, randomized,...

– Cash position of $86.1 million as of September 30, 2024, not including cash R&D tax credit of $12.8 million received in October 2024 –         LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) — Achilles Therapeutics plc (NASDAQ: ACHL) today announced its financial results for the third quarter ended September 30, 2024, and recent corporate updates. Corporate UpdatesFollowing the discontinuation of its TIL-based cNeT program and closure of the Phase I/IIa CHIRON and THETIS clinical trials, the Company has engaged BofA Securities as a financial advisor in the process of exploring strategic options. Achilles Chief Scientific Officer, Sergio Quezada, presented “Targeting Clonal Neoantigens with Precision T-Cell Therapies: Key Mechanistic Insights From cNeT Clinical Trials” in a seminar on October 23, 2024 at the 6th Annual TIL Therapies...

–– ORLYNVAHTM Approved by FDA on October 25, 2024— –Company to Host Conference Call Today at 8:30 a.m. EDT– DUBLIN and CHICAGO, Nov. 14, 2024 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), (Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the third quarter ended September 30, 2024. “With last month’s approval of ORLYNVAHTM, we have renewed our outreach to potential strategic partners,” said Corey Fishman, Iterum’s Chief Executive Officer. “As the only oral penem antibiotic approved for commercial sale in the U.S. and the potentially first branded uncomplicated urinary tract infection (uUTI) product to enter this underserved...

On Track for Catalyst-Rich Q4 MONTREAL, Nov. 14, 2024 (GLOBE NEWSWIRE) — Aya Gold & Silver Inc. (TSX: AYA, OTCQX: AYASF) (“Aya” or the “Corporation”) is pleased to announce interim financial and operational results for the third quarter ended September 30, 2024. All amounts are in US dollars, unless otherwise stated. Q3-2024 HighlightsContinued advancing Zgounder Mine expansion on budget:Expansion of Zgounder Mine over 99% complete and commissioning well underway. Targeting commercial production in late Q4-2024.Delivered a transitional quarter:Silver production of 355,927 ounces (“oz”). Ore processed increased to 83,352 tonnes (“t”), a new quarterly record. 120,985t of ore mined in the quarter for an average of 1,315 tonnes per day (“tpd”). Revenue of $11 million, a 6% decrease from Q3-2023. Robust financial position...

MONTREAL, Nov. 14, 2024 (GLOBE NEWSWIRE) — Boralex Inc. (“Boralex” or the “Company”) (TSX: BLX) is pleased to report its results for the third quarter and nine-month period ended September 30, 2024. Highlights Third quarter financial resultsEBITDA(A)1, operating income and net earnings under pressure in Q3-2024 owing to adverse weather conditionsProduction down 3% (1% on a combined1 basis)2 from Q3-2023; total production 14% (11%) below anticipated production1 due primarily to adverse wind conditions in Canada and France as well as increased curtailments at certain wind farms. EBITDA(A) of $87 million ($109 million on a combined basis) in Q3-2024, down $3 million ($4 million) from Q3-2023, with the decrease in production partially offset by the contribution of newly commissioned sites in France and the positive impact of the...

NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced results for the third quarter 2024. MiNK will host a conference call and webcast at 8:30 a.m. ET. “Our progress this quarter reflects MiNK’s commitment to advancing effective and scalable therapies in cancer and immune-mediated diseases,” said Jennifer Buell, PhD, Chief Executive Officer of MiNK Therapeutics. “We have continued to expand our iNKT cell therapy platform and partnerships to address high-need areas, recently showcasing the versatility of iNKT cells in two presentations at SITC. Our clinical...

 – Announced development of SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A; IND filing expected in Q3’2025 –  – Cash balance of approximately $90M as of September 30, 2024; expected to fund operations into 2027 – AUSTIN, TX and DURHAM, NC, Nov. 14, 2024 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with cancer and chronic immune-related diseases, today reported financial results for the quarter ended September 30, 2024 and provided recent business highlights. “Last month we announced a strategic shift to focus on the development of SL-325, a first-in-class DR3 blocking antibody designed to achieve a more complete blockade...

SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025 Active clinical trial sites now enrolling patients directly into SOL-R Cash balance of $427.2M as of September 30, 2024, expected to fund operations into 2028 Ocular to host a Q3 2024 conference call and webcast today, November 14th, at 8:00 AM ET BEDFORD, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today reported financial results for the third quarter ended September 30, 2024 and provided recent business highlights, including an update on the Phase 3 registrational program for AXPAXLI™...

Optimizing Costs and Inventory, Well-positioned Entering Fiscal Year 2025 Fiscal Year 2024 HighlightsRevenue decreased 8% to $1.78 billion Same-store sales decreased 7% Gross profit margin of 24.5% GAAP net loss of $6 million, or $(0.39) per diluted share and adjusted diluted earnings per share1 of $0.98 Adjusted EBITDA1 was $82 millionBUFORD, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) — OneWater Marine Inc. (NASDAQ: ONEW) (“OneWater” or the “Company”) today announced results for its fiscal fourth quarter and year ended September 30, 2024. “Our team demonstrated remarkable resilience and execution amidst a challenging retail environment as consumer behavior and industry inventory reset in fiscal 2024. Our revenue and brand diversification, coupled with our geographic reach, helped mitigate the impact of macroeconomic uncertainty and...

Accelsius delivered first revenue generating system during third quarter ORLANDO, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) — Innventure, Inc. (NASDAQ: INV) (“Innventure”), a technology commercialization platform, today announced financial results for the quarter ended September 30, 2024. “We are incredibly excited about Innventure’s accomplishments during the third quarter, which subsequently culminated in early October with the close of our business combination and first day of trading on the Nasdaq,” said Bill Haskell, Innventure’s Chief Executive Officer. “Our operating companies continue to outperform our expectations, with both AeroFlexx and Accelsius now delivering commercial product to the marketplace.” Mr. Haskell continued, “We look forward to sharing more as we scale these companies and launch new companies in the future....